Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies

Rheumatology and Therapy · Published 2026-07-31 · DOI 10.1007/s40744-026-00874-x

Free full text

Authors (11)

Gerd R. Burmester, James Galloway, Karen Bevers, Jérôme Avouac, Susana Romero-Yuste, Roberto F. Caporali, Neil Betteridge, Carole Van der Donckt, Thomas P. A. Debray, Ouafia Tandjaoui Bouzid, Patrick Verschueren

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Burmester, G., Galloway, J., Bevers, K., et al. (2026). Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies. Rheumatology and Therapy. https://doi.org/10.1007/s40744-026-00874-x

Related articles

• Effectiveness and Safety of Inebilizumab for IgG4-Related Disease in a Real-World Clinical Setting in Japan: Protocol for a Long-Term Prospective Observational Study (4SigHT Study) · Rheumatology and Therapy · 2026 · Same journal
• Does Prior Exposure Affect Retention? A Real-World, Multicentre Assessment of IL-17 Inhibitor Cycling in Psoriatic Arthritis · Rheumatology and Therapy · 2026 · Same journal
• Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL Study · Rheumatology and Therapy · 2026 · Same journal
• Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials · Rheumatology and Therapy · 2025 · Same journal
• Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS Studies · Rheumatology and Therapy · 2026 · Same journal
• Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials · Rheumatology and Therapy · 2025 · Same journal
• Long-term Effectiveness and Safety of Canakinumab in Patients with TRAPS: Analysis of the RELIANCE Non-Interventional Study · Rheumatology and Therapy · 2025 · Same journal
• Real-World Effectiveness and Satisfaction with Risankizumab for the Treatment of Psoriatic Arthritis in Biologic-Naïve Patients: A Population Survey in the United States and Europe · Rheumatology and Therapy · 2025 · Same journal
• Diuretic-Induced Hypomagnesemia May Play a Key Role in the Development of Calcium Pyrophosphate Arthritis · Rheumatology and Therapy · 2026 · Same journal
• Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials · Rheumatology and Therapy · 2025 · Same journal